Solifenacin succinate
905-CL-047
Phase 3 small_molecule completed
Quick answer
Solifenacin succinate for Neurogenic Detrusor Overactivity is a Phase 3 program (small_molecule) at Astellas Pharma Europe B. V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Astellas Pharma Europe B. V.
- Indication
- Neurogenic Detrusor Overactivity
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed